CSI Market
Sign In | Register

Takeda Pharmaceutical Limited (TAK) Annual Income Statement

Annual · GAAP · USD millions
Access TAK quarterly income statements →
From Takeda Pharmaceutical Limited through Mar 31 2021, changes in Mar 31 2025's revenue and cost structure provide insight into profitability trends.
View historic periods: Download as CSV:
Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.
Annual Report, GAAP in USD millions
ITEM 		(Mar 31 2025)
2025 		(Mar 31 2024) (Mar 31 2023) (Mar 31 2022) (Mar 31 2021)
Revenues
Sales of Products30,079.37
Total Revenue30,079.37
Costs & Expenses
Cost of Goods and Services Sold10,374.64
Gross Profit19,118.12
Depreciation & Amortization5,028.67
Research and Development Expense-4,651.45
Other Operating Expense / -Income32,721.87
Total operating costs including COS27,830.18
Operating income / -loss2,249.19
Net Interest (-)Expense / Income0.00
Loss / -Gain on Investment2.27
Foreign Currency Transaction (Gain) Loss-29.51
Other loss / -income-1,291.47
Total costs & expenses28,068.64
Income & Taxes
Income / -loss before income taxes1,149.48
Income taxes expenses / -benefit439.49
Income after income taxes709.99
Net income / -loss of other equity0.00
Income / -loss from continuing operations709.99
Non-controlling interests2.42
Net income / -loss709.99
Income / -loss to shareholder708.58
EBIT1,149.48
EBITD1,149.48
EBITDA1,149.48
Earnings Per Share
Basic EPS (excl. extra items)0.44
Basic Net EPS0.44
Basic shares outstanding (Mill. of Units)1,578.87
Diluted Net EPS0.43
Diluted average shares (Mill. of Units)1,605.32
Dividend per share1.20
4 historic quarters locked

Sign in to unlock the full Takeda Pharmaceutical Limited income statement history.

Sign In Create Free Account

About TAK Annual Income Statement

What this statement shows

This page presents issuer-reported income statement data, detailing revenue, operating costs, expenses, and earnings as disclosed in SEC 10-K filings and standardized by CSIMarket. The income statement reflects operating performance over a reporting period rather than financial position at a single date.

Revenue and expense treatment

Revenue and expense items are aligned to support period-to-period comparability. Operating and non-operating items, interest, and income taxes are classified based on issuer disclosures and XBRL tagging.

Source & verification

  • Source: SEC 10-K filings
  • Filed with the SEC: n/a

Income statement figures represent operating results for each reporting period and may be revised in subsequent filings.

Get the full CSIMarket dataset: Subscribe API License